Shares of ImmuPharma plc (LON:IMM – Get Free Report) fell 10.2% on Friday . The company traded as low as GBX 1.24 ($0.02) and last traded at GBX 1.28 ($0.02). 2,845,345 shares were traded during trading, an increase of 64% from the average session volume of 1,739,931 shares. The stock had previously closed at GBX 1.43 ($0.02).
ImmuPharma Price Performance
The stock has a market capitalization of £5.11 million, a price-to-earnings ratio of -122.80 and a beta of 1.53. The firm’s fifty day moving average is GBX 1.72 and its 200-day moving average is GBX 1.86.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Recommended Stories
- Five stocks we like better than ImmuPharma
- Energy and Oil Stocks Explained
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- Stock Sentiment Analysis: How it Works
- MarketBeat Week in Review – 11/25 – 11/29
- What is a buyback in stocks? A comprehensive guide for investors
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
